|
Patent landscape, scope, and claims: |
Patent Landscape and Scope Analysis of US Patent 10,278,923
Summary:
US Patent 10,278,923, titled "Methods of Treating Inflammatory and Autoimmune Disease," filed on March 25, 2016, and granted on May 14, 2019, claims a novel class of compounds and methods for treating inflammatory conditions. The patent primarily covers specific small-molecule inhibitors targeting the Janus kinase (JAK) family, particularly JAK1 and JAK2. The patent scope encompasses compound composition claims, methods of treatment, and pharmaceutical formulations. Its claims aim to secure exclusive rights over certain chemical structures, their use in treating autoimmune diseases, and specific dosage regimens. The patent landscape features multiple filings around JAK inhibitors, with notable differentiation in chemical structure and intended therapeutic applications.
What Is the Scope of US Patent 10,278,923?
Chemical Composition Claims:
- Claims 1-10 cover a group of heteroaryl compounds with specific structures, including substitutions on core aromatic rings.
- These compounds are defined by particular chemical moieties and stereochemistry, focusing on inhibitors of Janus kinase enzymes.
- The scope explicitly includes compounds with select substitutions that confer activity against JAK1 and JAK2.
Therapeutic Use Claims:
- Claims 11-20 detail methods of using the compounds to treat inflammatory, autoimmune, and allergic diseases, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
- The claims specify administering effective amounts of the compounds.
- Certain claims specify human subjects, dosage forms, and treatment regimens.
Pharmaceutical Composition Claims:
- Claims 21-25 cover pharmaceutical formulations comprising the compounds, including tablets, capsules, and injectable forms.
- The scope extends to combination therapies with other immunomodulatory agents.
Method of Synthesis:
- Claims 26-30 describe synthetic routes to the claimed compounds, though these are more secondary and narrower in scope.
Claims Limitations:
- The patent limits claims to compounds with specific substitutions, stereochemistry, and certain pharmacokinetic profiles.
- Broad generic claims are avoided, favoring a narrow scope centered around novelty and specific compound configurations.
Patent Landscape: Related Patents and Patent Families
Key Similar Patents:
- US Patent 9,971,934 (granted June 19, 2018): Covers broader classes of JAK inhibitors, including different heterocyclic compounds.
- WO2016078634 (PCT Application): Discloses various JAK inhibitors with structures similar to those in 10,278,923, focusing on autoimmune indications.
- US Patent 10,509,056: Filed in 2018, claims additional chemical analogs and combination therapies.
Major Assignees:
- Pfizer Inc.: Multiple filings related to tofacitinib and other JAK inhibitors.
- Eli Lilly and Company: Focused on selective inhibitors and therapeutic methods.
- Other biotech firms focusing on JAK-STAT pathway inhibitors.
Patent Family Coverage:
- The patent family around US 10,278,923 includes filings in Europe (EP), Japan (JP), China (CN), and elsewhere, emphasizing global protection.
- The family extends claims to methods of synthesis and pharmaceutical use, with international patents varying in scope.
Legal Status & Expiry:
- The patent is active until 2036, considering pediatric extension rights and potential terminal disclaimers.
- No substantial legal challenges or oppositions are publicly documented.
Analysis of Claim Breadth and Innovation
Novelty and Inventive Step:
- The patent introduces specific heteroaryl compounds not found in prior art, with unique substitutions enhancing selectivity for JAK1/JAK2.
- The therapeutic claims leverage unexpected selectivity for inflammatory disorders, representing an advance over earlier broad-spectrum JAK inhibitors.
Potential Overlaps:
- Overlaps exist with existing JAK inhibitors such as tofacitinib and baricitinib, but the specific chemical structures and claimed methods mitigate the risk of infringement or invalidation.
- Narrow claims related to particular chemical configurations reduce prior art obstacles.
Claims Scope Limitations:
- The reliance on specific chemical structures limits the patent's breadth but enhances validity.
- Use claims are dependent on the structural claims, consistent with U.S. patent practice.
Strategic Implications for Stakeholders
- R&D: The patent consolidates rights over a specific class of JAK inhibitors, guiding future compound design within the claimed chemical space.
- Licensing & Partnerships: The scope provides a foundation for licensing negotiations, especially for autoimmune disease therapeutics.
- Generic Developers: Limited scope offers a pathway to design around by modifying chemical structures outside the claims' scope.
- Patent Expiry & Market Entry: Expiry is projected around 2036, making the patent a key barrier through the next decade, with potential for extensions or supplementary protection.
Key Takeaways
- US 10,278,923 claims specific heteroaryl compounds as JAK inhibitors with therapeutic applications in inflammatory diseases.
- The scope encompasses compound structure, method of use, pharmaceutical compositions, and synthesis methods with narrow, specific claims.
- The patent landscape is dense within the JAK inhibitor space, with competition mainly from compounds with different chemical backbones.
- Its strength lies in chemical specificity rather than structural broadness, influencing R&D strategies and licensing approaches.
- The patent remains a key asset until 2036, shaping the competitive landscape for next-generation JAK inhibitors.
FAQs
1. How does US 10,278,923 differ from other JAK inhibitor patents?
It claims specific heteroaryl compounds with particular substitutions, providing narrower, more targeted scope than broader JAK inhibitor patents.
2. Can competitors develop similar compounds outside the scope of this patent?
Yes, by designing molecules that do not match the chemical structures claimed, competitors can potentially avoid infringement.
3. What diseases are targeted by the claimed methods?
Primarily autoimmune and inflammatory diseases, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
4. Are the synthesis methods protected by patent claims?
Yes, but these are more narrowly focused on specific synthetic routes, primarily supporting the chemical claims.
5. How long until this patent expires?
Assuming no extensions, it is expected to expire in 2036, barring further patent term extensions.
References:
- U.S. Patent and Trademark Office. (2019). US 10,278,923 B2.
- WIPO Patent WO2016078634 A1. (2016).
- Eli Lilly and Company. (2018). US 10,509,056 B2.
- Pfizer Inc. (2018). US 9,971,934 B2.
More… ↓
⤷ Start Trial
|
